X

Trial Profile

A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltoprazine (Primary)
Indications Dyskinesias; Parkinson's disease
Focus Proof of concept; Therapeutic Use
Sponsors PsychoGenics

Most Recent Events

17 Apr 2017 Results published in an Amarantus Bioscience Holdings media release.
18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
15 Jun 2015 According to Amarantus Biosciences Holdings media release, data from this phase I/IIA study was poster presented at the 19th International Congress of Parkinson's Disease and Movement Disorders 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com